Ongoing phase 1/2 trial of the hematopoietic progenitor kinase 1 (HPK1) inhibitor NDI-101150 as monotherapy or in combination with pembrolizumab: Clinical safety and efficacy update in clear cell renal cell carcinoma (ccRCC).David A. Braun, David Sommerhalder, Kurt C. Demel et al.|Journal of Clinical Oncology|2025Cited by 1
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial resultsDavid A. Braun, David Sommerhalder, Arif Hussain et al.|Cell Reports Medicine|2026Cited by 1
Abstract CT022: First data disclosure of the Phase I trial of the first in class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterationsTimothy A. Yap, Alison M. Schram, Rahul Aggarwal et al.|Cancer Research|2026Cited by 0